BRAIN Biotech : Investor Call Presentation

BRAIN Biotech AG

Pioneering Bio-based Products

Investor Call Genome Editing Tool developed by BRAIN

Adriaan Moelker, CEO

Lukas Linnig, CFO

Dr. Michael Krohn, Head R&D

Zwingenberg, May 7th ,2021

Pioneering Bio-based Products.	© BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com [phone]	1

Safe Harbor Statement

This document may contain forward-looking statements. These forward-looking statements are subject to risks and uncertainties, as they relate to future events and are based on current assumptions of the Company, which may not occur at all in the future or may not occur as assumed. They do not represent a guarantee for future results or performance of the Company, and the development of economic and legal conditions may materially differ from the information expressed or implied in the forward-looking statements.

The Company assumes no obligation to update or revise any forward-looking statement contained herein or to adapt them to future events or developments. The information contained in this document has not been independently verified. No representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinion contained herein. The Company or any of its shareholders, affiliates, advisors, employees or representatives shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its content or otherwise arising in connection with this document.

By accepting this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsibility for forming your own view of the potential future performance of the Company's business.

This presentation speaks as May 7th, 2021. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since such date. The term "BRAIN", as used in this presentation means BRAIN Biotech AG and its affiliates, if not otherwise specified.

Pioneering Bio-based Products.

© BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com [phone]

2

Genome Editing - developed by BRAIN

Simple Introduction to CRISPR-Cas Technology

Genome Editing: directed and precise change or use of a chromosomal target in a given organism

CRISPR = clustered regularly interspaced short palindromic repeats

CAS = CRISPR associated sequence

CRISPR-Cas systems have enabled genome editing in multiple species and provided genetic tools with speed as well as simplicity that were previously unavailable

Editing requires only two components (1. Cas nuclease 2. programmable guide RNA), and can be multiplexed for simultaneous modification of multiple sites in a single transformation event

CRISPR-Cas systems can be used to edit a genome through gene knockouts or homology- mediated knockins to control transcription of exogenous or endogenous genes

Industrial Biotechnolgy Significance: CRISPR-Cas-mediated engineering can increase the number of chemicals and products that are accessible through fermentation and broaden the diversity of strains suitable for industrial production

Pioneering Bio-based Products.

© BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com [phone]

3

Genome Editing - developed by BRAIN

BRAIN's Novel CRISPR-Cas

• Novel CRISPR Cas system developed using metagenomics sequencing and protein engineering
• Non-Cas9 type genome editing nuclease
• Scarless gene modification at the single nucleotide level
• In-housedesigned application tools and strategies
• Development of customized screening cells for target identification / validation or bioactive product development / identification
• State of the art technology for the development of high performance producer strains

BRAIN has extensive practical experience with Genome-

Editing Technologies

Pioneering Bio-based Products.

© BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com [phone]

4

Genome Editing - developed by BRAIN

BRAIN's CRISPR-Cas, Status Quo

Status Quo

• Today validated as a genome editing tool in selected bacteria, fungi and yeast
• Today demonstrated DNA targeting activity in selected bacteria, fungi and yeast
• Technology already employed in internal projects
• Activity in plants has been achieved but still needs to be validated
• Genome editing activity tests ongoing for additional applications incl. mammalian cell lines
• First IP application to protect the Brain developed CRISPR associated nuclease (BEC) sequence is already submitted
• Currently developing system to work as a genome editing tool in BRAIN related strains
• International Partner for plant cells involved since the beginning of the program (non disclosed)
• Could open up application fields where classical Cas proteins are not suitable
• Explore multiplex metabolic pathway engineering / redirection
• Off target analysis running & further mode of action studies are necessary

Pioneering Bio-based Products.

© BRAIN Biotech AG Zwingenberg Germany www.brain-biotech.com [phone]

5